Delcath Systems (NASDAQ:DCTH) Stock Price Expected to Rise, HC Wainwright Analyst Says

Delcath Systems (NASDAQ:DCTH) had its target price boosted by HC Wainwright from $22.00 to $24.00 in a report issued on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, Craig Hallum lifted their price target on shares of Delcath Systems from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Friday, January 17th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Delcath Systems currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.75.

Delcath Systems Stock Performance

Shares of Delcath Systems stock opened at $13.00 on Friday. Delcath Systems has a fifty-two week low of $3.70 and a fifty-two week high of $16.97. The firm has a market capitalization of $415.66 million, a price-to-earnings ratio of -9.63 and a beta of 0.82. The stock has a 50 day moving average of $14.40 and a 200 day moving average of $11.63.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings data on Thursday, March 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). The business had revenue of $15.10 million for the quarter, compared to analyst estimates of $14.96 million. Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. During the same period in the previous year, the business posted ($0.48) earnings per share. Analysts forecast that Delcath Systems will post -0.79 EPS for the current year.

Institutional Investors Weigh In On Delcath Systems

Hedge funds and other institutional investors have recently made changes to their positions in the business. Quarry LP acquired a new position in shares of Delcath Systems in the 4th quarter valued at $34,000. Quantbot Technologies LP acquired a new position in shares of Delcath Systems during the fourth quarter worth about $66,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Delcath Systems during the third quarter worth about $102,000. Barclays PLC acquired a new stake in Delcath Systems in the third quarter valued at about $104,000. Finally, Jane Street Group LLC purchased a new stake in Delcath Systems in the 3rd quarter valued at approximately $110,000. Institutional investors and hedge funds own 61.12% of the company’s stock.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.